全文获取类型
收费全文 | 16795篇 |
免费 | 934篇 |
国内免费 | 125篇 |
专业分类
耳鼻咽喉 | 157篇 |
儿科学 | 340篇 |
妇产科学 | 483篇 |
基础医学 | 1974篇 |
口腔科学 | 413篇 |
临床医学 | 1284篇 |
内科学 | 5240篇 |
皮肤病学 | 434篇 |
神经病学 | 1310篇 |
特种医学 | 305篇 |
外科学 | 2325篇 |
综合类 | 106篇 |
一般理论 | 9篇 |
预防医学 | 1074篇 |
眼科学 | 310篇 |
药学 | 909篇 |
中国医学 | 37篇 |
肿瘤学 | 1144篇 |
出版年
2023年 | 127篇 |
2022年 | 95篇 |
2021年 | 645篇 |
2020年 | 333篇 |
2019年 | 650篇 |
2018年 | 707篇 |
2017年 | 422篇 |
2016年 | 444篇 |
2015年 | 475篇 |
2014年 | 769篇 |
2013年 | 866篇 |
2012年 | 1520篇 |
2011年 | 1540篇 |
2010年 | 803篇 |
2009年 | 716篇 |
2008年 | 1161篇 |
2007年 | 1174篇 |
2006年 | 1013篇 |
2005年 | 990篇 |
2004年 | 884篇 |
2003年 | 713篇 |
2002年 | 716篇 |
2001年 | 90篇 |
2000年 | 72篇 |
1999年 | 102篇 |
1998年 | 85篇 |
1997年 | 87篇 |
1996年 | 54篇 |
1995年 | 45篇 |
1994年 | 55篇 |
1993年 | 39篇 |
1992年 | 55篇 |
1991年 | 44篇 |
1990年 | 30篇 |
1989年 | 34篇 |
1988年 | 30篇 |
1987年 | 28篇 |
1986年 | 25篇 |
1985年 | 15篇 |
1984年 | 21篇 |
1983年 | 17篇 |
1982年 | 21篇 |
1981年 | 15篇 |
1980年 | 14篇 |
1979年 | 12篇 |
1975年 | 17篇 |
1974年 | 11篇 |
1973年 | 7篇 |
1971年 | 11篇 |
1967年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Francisco José Álvarez García María José Cilleruelo Ortega Javier Álvarez Aldeán María Garcés-Sánchez Nuria García Sánchez Elisa Garrote Llanos Ángel Hernández Merino Antonio Iofrío de Arce Abián Montesdeoca Melián María Luisa Navarro Gómez Jesús Ruiz-Contreras 《Anales de pediatría (Barcelona, Spain : 2003)》2021,94(1):53.e1-53.e10
The CAV-AEP annually publishes the immunisation schedule considered optimal for all children and adolescent resident in Spain, taking into account the available evidence.The 2 + 1 schedule is recommended (2, 4, and 11 months) with hexavalent vaccines (DTPa-VPI-Hib-HB) and with 13-valent pneumococcal conjugate.A 6-year booster is recommended, preferably with DTPa (if available), with a dose of polio for those who received 2 + 1 schemes, as well as vaccination with Tdpa in adolescents and in each pregnancy, preferably between 27 and 32 weeks.Rotavirus vaccine should be systematic for all infants.Meningococcal B vaccine, with a 2 + 1 schedule, should be included in routine calendar.In addition to the inclusion of the conjugated tetravalent meningococcal vaccine (MenACWY) at 12 years of age with catch up to 18 years, inclusive, the CAV recommends this vaccine to be also included at 12 months of age, replacing MenC. Likewise, it is recommended in those over 6 weeks of age with risk factors or who travel to countries with a high incidence of these serogroups.Two-dose schedules for triple viral (12 months and 3-4 years) and varicella (15 months and 3-4 years) will be used. The second dose could be applied as a tetraviral vaccine.Universal systematic vaccination against HPV is recommended, regardless of gender, preferably at 12 years, and greater effort should be made to improve coverage. The 9 genotype extends coverage for both genders. 相似文献
2.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
3.
Cifuentes-Faura Javier Di Francesco Renaud 《The European journal of health economics》2022,23(4):559-563
The European Journal of Health Economics - 相似文献
4.
5.
6.
7.
8.
9.
Samira Marín-Romero Teresa Elías-Hernández María Isabel Asensio-Cruz Rocío Ortega-Rivera Raquel Morillo-Guerrero Javier Toral Emilio Montero Verónica Sánchez Elena Arellano José María Sánchez-Díaz Macarena Real-Domínguez Remedios Otero-Candelera Luis Jara-Palomares 《Archivos de bronconeumología》2019,55(12):619-626
IntroductionScales for predicting venous thromboembolism (VTE) recurrence are useful for deciding the duration of the anticoagulant treatment. Although there are several scales, the most appropriate for our setting has not been identified. For this reason, we aimed to validate the DASH prediction score and the Vienna nomogram at 12 months.MethodsThis was a retrospective study of unselected consecutive VTE patients seen between 2006 and 2014. We compared the ability of the DASH score and the Vienna nomogram to predict recurrences of VTE. The validation was performed by stratifying patients as low-risk or high-risk, according to each scale (discrimination) and comparing the observed recurrence with the expected rate (calibration).ResultsOf 353 patients evaluated, 195 were analyzed, with an average age of 53.5 ± 19 years. There were 21 recurrences in 1 year (10.8%, 95% CI: 6.8%-16%). According to the DASH score, 42% were classified as low risk, and the rate of VTE recurrence in this group was 4.9% (95% CI: 1.3%-12%) vs. the high-risk group that was 15% (95% CI: 9%-23%) (p <.05). According to the Vienna nomogram, 30% were classified as low risk, and the rate of VTE recurrence in the low risk group vs. the high risk group was 4.2% (95% CI:0.5%-14%) vs. 16.2% (95% CI: 9.9%-24.4%) (p <.05).ConclusionsOur study validates the DASH score and the Vienna nomogram in our population. The DASH prediction score may be the most advisable, both because of its simplicity and its ability to identify more low-risk patients than the Vienna nomogram (42% vs. 30%). 相似文献
10.